

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Dislocated distal radial fractures in adult patients: Four weeks versus Six weeks of cast immobilisation following reduction, a multicenter randomized controlled trial.

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-026540
Article Type:	Protocol
Date Submitted by the Author:	22-Oct-2018
Complete List of Authors:	van Delft, Eva A.K.; Amsterdam UMC, Vrije Universiteit Amsterdam, Trauma surgery Bloemers, Frank; VU medisch centrum, Traumasurgery Sosef, Nico L; Spaarne Gasthuis, Trauma Surgery Bonjer, H.J. (Jaap); Amsterdam UMC, Vrije Universiteit Amsterdam, Surgery Schep, Niels W.L.; Maasstad Ziekenhuis, Trauma Surgery Vermeulen, Jefrey; Maasstad Ziekenhuis, Trauma Surgery
Keywords:	Adult orthopaedics < ORTHOPAEDIC & TRAUMA SURGERY, Hand & wrist < ORTHOPAEDIC & TRAUMA SURGERY, Orthopaedic & trauma surgery < SURGERY



Title:	Dislocated d	istal radial fractures in adult patients: Four weeks versus Six weeks of
	immobilisatio	on following reduction, a multicenter randomized controlled trial.
Acron	i ym: DR P	IP II study (Distal radius plaster immobilisation period)
Autho	ors and affilia	tions:
1.	E.A.K. van De	elft, MD, PhD candidate, surgical resident [corresponding author]
	Affiliation:	Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Tra
		Surgery, Amsterdam Movement Sciences
	Address:	Boelelaan 1117, Amsterdam, The Netherlands
	Email:	evavandelft@gmail.com
	Phone:	0031-20444444
2.	F.W. Bloemer	rs, MD, PhD, MSc, trauma surgeon
	Affiliation:	Amsterdam UMC, Vrije Universiteit Amsterdam,
		Department of Trauma Surgery
	Address:	Boelelaan 1117, Amsterdam, The Netherlands
	Email:	fw.bloemers@vumc.nl
3.	N.L. Sosef, M	D, trauma surgeon
	Affiliation:	Spaarne Gasthuis Hospital, Department of Surgery
	Address:	Boerhaavelaan 22, 2035 RC, Haarlem, The Netherlands
	Email:	nsosef@spaarnegasthuis.nl
4.	Prof. H.J. Bor	njer, MD, PhD, Professor of Surgery
	Affiliation:	Amsterdam UMC, Vrije Universiteit Amsterdam,
		Department of Surgery
	Address:	Boelelaan 1117, Amsterdam, The Netherlands
	Email:	j.bonjer@vumc.nl
5.	N.W.L. Schep	n, MD, PhD, MSc, trauma surgeon
	Affiliation:	Maasstad Hospital, Department of Trauma and hand surgery
	Address:	Maasstadweg 21, 3079 DZ, Rotterdam, The Netherlands
	Email:	schepn@maasstadziekenhuis.nl
6.	J. Vermeulen,	MD, PhD, MSc, trauma surgeon
	Affiliation:	Maasstad Hospital, Department of Trauma surgery
	Address:	Maasstadweg 21, 3079 DZ, Rotterdam, The Netherlands
	Email:	vermeulenj@maasstadziekenhuis.nl
Trial r	egistration:	Netherlands National Trial Register: NTR 6600, ABR: NL62861.029 Medical Ethical Committee VUmc registration number: 2018.004
Proto	col version:	2

Funding:no funding was obtained for this studyResponsibilities:Project leader: F.W. BloemersWord count:2023

Dislocated distal radial fractures in adult patients: Four weeks versus Six weeks of cast immobilisation following reduction, a multicenter randomized controlled trial.

ABSTRACT

Introduction: Up to 30% of patients with a dislocated distal radius fracture treated with closed reduction and cast immobilisation suffer from long-term functional restrictions. It remains unclear, whether duration of cast immobilisation influences functional outcome. The aim of this study is to evaluate whether the functional outcome of dislocated distal radial fractures could be improved by shortening the period of immobilisation.

Methods and analysis: A single blinded multicenter randomized controlled trial is initiated. Four weeks of plaster cast immobilisation is compared to six week plaster cast immobilisation in adult patient with adequately reduced distal radial fractures.

Primary outcome parameters are functional outcome measured with the Patient Related Wrist Evaluation after 1 year of follow up. Secondary outcomes are: Disability of Arm, Shoulder and Hand Score after one year, SF-36 after one year, functional outcome earlier in follow up (6 weeks, 12 weeks and 6 months), range of motion, pain level and complications (number of re-interventions, secondary displacement, non-/malunion).

Ethics and dissemination: The expectation of this study is that a shorter duration of plaster cast immobilisation is beneficial. This risk of specific complications is low and generally similar in both treatment options. Follow-up is standardized according to current trauma guidelines. Present literature indicates that both treatment options that are used within this study are accepted protocols for treatment of displaced distal radius fractures. This trial will provide level-1 evidence for the comparison of functional outcome between the two treatment options for dislocated distal radial fractures.

Trial registration:Netherlands National Trial Register: NTR 6600, ABR: NL62861.029.17Medical Ethical Committee VUmc registration number: 2018.004

1		
2		
3	Keywords:	Distal radial fractures, conservative treatment, immobilisation period
4	• -	,
5		
6		
7		
8		
9		
10		
11		
12		
12		
14		
14		
15		
10		
17		
1ð 10		
19		
20		
21		
22		
23		
24		
25		
26		
2/		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60	For p	eer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Strengths and limitations:

- Single blinded study
- Multicenter study
- This studies uses validated outcomes (PRWE, QuickDASH, SF-36)
- This studies uses both statistical as well as minimal clinical important difference
- This trial will provide level-1 evidence for the period of immobilisation in reduced distal radial fractures.

to beer terien only

INTRODUCTION

Distal radial fractures (DRF) are common fractures and account for up to 20% of all extremity fractures.[1] Most of these patients can be treated non-operatively in a plaster, with excellent functional results.[2,3] Nevertheless, up to 30% of patients with a dislocated DRF suffer from long-term functional restrictions following conservative treatment.[4]

Unstable DRF are liable to displace within the first two weeks, only 7-8% displace after this time and none after six weeks.[5-7] Therefore a period of up to six weeks of immobilisation is advised, although, this is still a matter of debate in literature.[8,9]

Two prospective studies of patients with displaced and reduced DRF showed that a shorter immobilisation period was safe, without increased numbers of (re)dislocation of the fracture. Besides, the outcome seemed to be better on the long term, in terms of wrist motion and grip strength.[8,10] Unfortunately these studies were non-randomized and conducted in heterogeneous groups of patients suffering both non-dislocated and dislocated fractures. Obviously, the ultimate treatment of reduced DRF is short, safe and leads to an early return of function. To assess whether reduction of the immobilisation period with two weeks will lead to better functional outcome, a multicenter randomized controlled trial is conducted.

The patient reported functional outcome after one year will be assessed using validated instruments: The Patient Rated Wrist Evaluation (PRWE), the Quick Disability of Arm and Shoulder (DASH) and SF-36 forms.[11-13] Other outcome measures are the functional outcome earlier in follow up, the amount of pain (VAS), number of secondary dislocations, number of re-interventions, range of motion, non-/malunion and complex regional pain syndrome (CRPS).

The aim of this trial is to compare the results of four weeks of cast immobilisation with six weeks of cast immobilisation in closed and adequately reduced DRF. Usually an immobilisation period of five or six weeks is preferred as non-operative treatment of closed and adequately reduced DRF. Despite the minimal evidence in literature this immobilisation period can be questioned. A randomized clinical trial with sufficient power is needed to provide scientific support for a preferred treatment strategy for reduced DRF.

METHODS AND ANALYSIS

This study will be conducted as a prospective single blinded multicenter randomized clinical trial in two large teaching hospitals. In this study four weeks of plaster immobilisation is compared with six weeks of plaster immobilisation.[Figure 1 and 2] Patients will be treated in a lower arm cast in neutral position.[14] Following immobilisation treatment will be the same for both groups, in which additional physiotherapy is advised and exercises to train wrist function will be given. The Medical Ethics Committee has approved the study protocol.

Patient and Public involvement

Evaluation of eligible patients will take place either at the emergency department or at the outpatient department. They will receive written information and a consent form from the attending physician, the clinical investigator or a research assistant. Patients are eligible if they follow the in- and exclusion criteria:

Inclusion criteria:

- 1. Age > 18 years;
- 2. Primary displaced unilateral DRF;
- 3. Independent for activities of daily living.

Exclusion criteria:

- 1. Fracture of the contralateral wrist;
- 2. Ipsilateral fractures proximal of the DRF;
- 3. Pre-existent abnormalities or functional deficits of the fractured wrist;
- 4. Open fractures.
- 5. Language ability to understand the Dutch patient information and questionnaires.

4.64

Patients can participate only if closed reduction of the distal radial fracture is adequately. The indication for reduction will be set, using the Lidström criteria for misalignment.[15] Patients can only participate in this study if reduction is performed successfully. Successful reduction will be classified as: radial shortening <3mm, dorsal tilt <10° or intra-articular step-off <2mm, according the guidelines of the American Association of Orthopedic Surgeons.[16]

After providing informed consent, eligible patients will be randomized after two weeks when the fracture has proven to be stable. An independent research assistant will perform concealed

permuted block randomisation using a computer-generated randomisation schedule after stratification for fracture type, gender and age. Allocation will be at random in four blocks. To prevent bias, stratification by age (younger and older than 60 years) and gender will be performed.[table 1]

Table 1:	Stratification by gender and age (younger and older than 60 years)
----------	--

Stratifi	Stratification by gender and age			
Patier	t characteristics	Randomization		
List 1	Male <60 y.o.a.	ABAB AABB ABBA BABA BAAB		
List 2	Male >60 y.o.a.	BAAB BBAA ABAB AABB ABBA		
List 3	Female <60 y.o.a.	AABB ABBA BAAB BBAA BABA		
List 4	Female >60 y.o.a.	ABBA BABA ABAB AABB AABB		
A = fou	A = four weeks, B = six weeks			

Randomisation between another 2 or 4 weeks cast immobilisation will be performed to complete a total of 4 and 6 weeks of cast immobilisation, respectively. Randomisation will occur after informed consent.

The primary outcome measure of this study is PRWE after one year.[11] The secondary outcome measures are The QuickDASH score after one year[12]; The SF-36 Healthy Survey after one year[13]; Functional outcome after 8 weeks, 3 months and 6 months; Range of motion; Pain level after 8 weeks, 3 months, 6 months and 1 year; Lidström-score[15]; and fracture related complications as secondary dislocation after cast removal, number of re-interventions, delayed and non-unions and CRPS.

PRWE score is the most responsive instrument for evaluating the outcome in patients with DRF. The PRWE is a validated 15-item (scored 1-10), self-reported questionnaire designed to help describe the disability experienced by people with disorders of the wrist and also to monitor changes in symptoms and function over time. Scores will be transformed to a 0-100 score.[11] A higher score indicates greater disability.

The DASH Outcome Measure is a validated 30-item, self-reported questionnaire designed to help describe the disability experienced by people with upper-limb disorders and also to monitor changes in symptoms and function over time.[16] The QuickDASH is a shortened version of the DASH Outcome Measure. Instead of 30 items, the QuickDASH uses 11 items (scored 1–5) to

BMJ Open

measure physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb. At least 10 of the 11 items must be completed for a score to be calculated. The scores will be transformed to a 0–100 scale for easy comparison. A higher score indicates greater disability.[12]

The SF-36 is a validated 36-item, self-reported questionnaire designed to describe the quality of life. The score consists eight subgroups: vitality, mental health social role, emotional role, physical role, general health, bodily pain, physical functioning. The subgroups are transformed to a 0-100 scale. The lower the score the more disability, an higher score indicates less disability.[13]

After inclusion, all patients will be followed for one year in total. Clinical assessments will occur at the time of admission (ED), one week (3-10-day window), two weeks (11-18-day window), four weeks (24-32-day window) or six weeks (5-7-week window), three months (11-15-week window), six months (5-7-month window), and 12 months (11-14-month window) after inclusion.

At each follow up (FU) visit, the research coordinator or research assistant will ascertain patient status (i.e., secondary interventions, adverse events/complications, deaths) and will verify information within medical records. All adverse events will be addressed to the principal investigator.

At each FU visit, the patients will be asked to indicate the actual pain level on a VAS. Patients will also be asked if they have any complaints of their treatment and will be asked if they are currently treated by a physical therapist. At each visit from eight weeks onwards, the range of motion of the wrist will be measured using a goniometer. In addition, patients will be asked to complete the questionnaires relating to disability (QuickDASH score, PRWE, SF-36).

Plain X-rays of the wrist will be made at the time of presentation in the hospital (ED), after one and two weeks, 4 or 6 weeks and at the follow-up visit after eight weeks, three months, six months and one year. The X-ray at one year will be taken in order to determine the grade of degenerative joint changes. Time to define the presence of a delayed- or malunion will be at three or six months.[figure 1-3]

The primary outcome will be the Patient Related Wrist Evaluation Score, of which the minimal clinically important difference is 11.5 points. The standard deviation of the PRWE is 14.0.[17] Based on a difference of 11.5 points, the sample size of 27 patients per treatment group was

calculated with a power $(1-\beta)$ of 80 percent and a type I error (α) of 5 percent, allowing for 10 percent drop-out. In this study, we decided to include 45 patients per treatment group. To allow a 10 percent drop-out in this study, in total 100 patients will be included.

Data from the demographic data collection and the outcome parameters will be cleaned blindly from the treatment data. Data are presented as mean scores with 95% confidence intervals. The analysis of this study will be carried out according to the intention-to treat principle, i.e. the patients will remain in the group they will be randomly allocated to at baseline. Analysis of functional outcome will be assessed using repeated-measures analysis of variance (GLM 4) with the time as the within-group factor and the treatment as the between-group factor. Posthoc analysis will be performed on the time of randomisation. Group comparisons at the different time points will be made only when the overall repeated-measures tests are statistically significant. All scores will be tested for normality using the Kolmogorov-Smirnov test. Parametric variables will be compared using the Student's t-test, while non-parametric and ordinal variables will be compared using the Mann–Whitney U statistic. Nominal variables will be compared across independent groups using the chi-squared test or Fisher's exact test. Homogeneity of variance will be assessed using Levene's test. Also, a multiple regression will be performed. SPSS statistical software (version 24.0) will be used for the analysis, in which two-tailed P value < 0.05 will be considered significant.

ETHICS AND DISSEMINATION

Present literature indicates that four weeks of immobilisation as well as six weeks of immobilisation are both accepted protocols for treatment of displaced DRF. In daily practise, a six weeks immobilisation period is mostly used. To assess the clinical controversy on this duration of treatment, this study was initiated.

The studies done for assessing the immobilisation periods of DRF have their limitations of using non-validated outcome score lists, which makes it impossible to conclude with certainty shorter immobilisation periods of DRF are preferred.

The expectation of this study is that a shorter duration of plaster cast immobilisation is beneficial for the patients. This risk of specific complications is low and generally similar in both treatment options.

The Medical Ethical Committee VUmc has approved the study protocol (2018.004). This trial will provide level-1 evidence for the comparison of functional outcome between the two treatment options for dislocated DRF.

REFERENCES

- **1.** Meena S, Sharma P, Sambharia AK, Dawar A, Fracture of Distal Radius: An overview. *J Family Medicine and Primary Care*, 2014; 3(4): 325-332.
- 2. Cooney WP, Management of Colles' fractures. J Hand Surg Br, 1989;14(2): 137–139.
- **3.** McQueen M, Caspers J, Colles fracture: does the anatomical result affect the final function? *J Bone Joint Surg*, 1988; 70(4): 649–651.
- 4. Cooney WP, James M.D, Dobyns J.H, Linscheid R.L, Complications of Colles fractures. *J Bone Joint Surg Am*, 1980; 62(4): 613-619.
- **5. Solgaard S**, Early displacement of distal radius fracture. *Acta Orthopedica Scandinavia,* 1986; 57(3): 229–231.
- 6. Abbaszadegan H, Sivers KV, Jonsson U, Late displacement of Colles' fractures. *Int Orthopedics*, 1988; 12(3): 197–199.
- **7.** Solgaard S, Function after distal radius fracture. *Acta Orthop Scand,* 1988; 59(1): 39–42.
- 8. McAuliffe TB, Hilliar KM, Coates CJ, Grange WJ, Early mobilisation of Colles' fractures. *J Bone Joint Surg Br*, 1987; 69(5) :727-729.
- **9.** Christensen OM, Christiansen TG, Krasheninnikhoff M, Hanssen FF, Length of immobilization after fractures of the distal radius. *Int Orthop*, 1995;19(1): 26-9.
- **10. Vang Hansen F, Staunstrup H, Mikkelsen S**, A comparison of 3 and 5 weeks immobilisation for Older type 1 and 2 Colles' fractures. *J Hand Surg Br,* 1998; 23(3): 400-401.
- **11. MacDermid JC, Turgeon T, Richards RS, Beadle M, Roth JH**, Patient rating of wrist pain and disability: a reliable and valid measurement tool. *J Orthop Trauma*, 1998; 12(8): 577–586.
- **12. Gummesson C, Ward MM, Atroshi I,** The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH): validity and reliability based on responses within the full-length DASH. *BMC Musculoskelet Disord*, 2006; 7-44.
- 13. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E, Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease, *J Clin Epidemiol*, 1998; 51(11): 1055-1068.
- **14. Handol HHG, Madhok R,** Conservative interventions for treating distal radial fractures in adults. *Cochrane Database of Systematic Reviews,* 2003; (2):CD000314
- **15. Lidström A,** Fractures of the distal end of the radius: a clinical and statistical study of end results. *Acta Orthop Scand Suppl,* 195; 41:1–118.
- **16. AAOS**, The treatment of distal radius fractures, guideline and evidence report, December 5, 2009.
- 17. Walenkamp MM, de Muinck Keizer RJ, Goslings JC, Vos LM, Rosenwasser MP, Schep MW, The minimum clinically important Difference of the Patient-rated Wrist EvaulationSccore for Patients with distal radius fractures, *Clin Orthop Relat Res.* 2015 473(10):3235-41
- **18. World medical association declaration of Helsinki:** ethical principles for medical research involving human subjects. *J Postgrad Med 2002*, 48:206–208.

-	
3	
4	
6	
7	
8	
9	
11	
12	
13	
14	
16	
17	
20	
21	
22	
23	
25	
26	
27	
29	
30	
31	
32	
34	
35	
30	
38	
39	
40 41	
42	
43	
44	
46	
47	
48	
49 50	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

AUTHORS CONTRIBUTIONS

E.A.K. van Delft:	Study development, writing study protocol,
	Clinical investigator in Amsterdam UMC, VU Medical Center
F.W. Bloemers:	Project leader, corrections of study protocol
N.L. Sosef:	First clinical investigator in Spaarne Gasthuis
<u>Prof. H.J. Bonjer:</u>	Head of department of Surgery Amsterdam UMC, VU Medical Center
	Approval of the study protocol
N.W.L. Schep:	Study development
J. Vermeulen:	Initial first clinical investigator in Spaarne Gasthuis,
	study development, Corrections of study protocol

LIST OF ABBREVIATIONS

AAOS	American Association of Orthopedic Surgeons
ABR	ABR form, General Assessment and Registration form, is the application form that is required for submission to the accredited Ethics Committee (In Dutch, ABR = Algemene Beoordeling en Registratie)
AVG	Algemene verordening gegevensbescherming (Dutch Data Protection Act)
CRPS	Complex regional pain syndrome
DASH	Disability of Arm, Shoulder and Hand
ED	Emergency Department
IC	Informed Consent
METC	Medical research ethics committee (MREC)
NTR	Nederlands Trial Register
PRWE	Patient Related Wrist Evaluation
qDASH	Quick Disability of Arm, Shoulder and Hand
QuickDASH	Quick Disability of Arm, Shoulder and Hand
SPSS	Statistical Package for the Social Sciences
VAS	Visual analog scale
VUmc	Vrije Universiteit Medical Center Amsterdam
X-ray	Radiography
-	

FIGURE LEGENDS

- Figure 1 Inclusion procedure
- Figure 2 Control of alignment and randomization procedure
- Figure 3 Follow-up scheme four versus six weeks of plaster cast immobilization

BMJ Open

Ethics approval and consent to participate:

The study is submitted to the Medical Ethics Committee VU Medical Center Amsterdam and Regional Ethical Committee and will be carried out in compliance with the Declaration of Helsinki on Ethical principles for medical research involving human subjects. [18] The Medical Ethics Committee VU Medical Center Amsterdam acts as central ethics committee for this trial (reference number: NL62861.029.17)

Consent for publication:

All patients will provide informed consent before participation in the trial. The data will be coded by patient number. Research data will be stored in a database (IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. Released 2013), and will be handled confidentially and anonymously.

Availability of data and materials:

The data will be coded by patient number. Research data will be stored in a database (IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. Released 2013), and will be handled confidentially and anonymously. Research data that can be traced to individual persons can only be viewed by authorized personnel. These persons are the members of the research team, members of the health care inspection, and members of the Medical Ethics Committee of the Amsterdam UMC, VU Medical Center Amsterdam. Review of the data may be necessary to ensure the reliability and quality of the research. The handling of personal data is in compliance with the Data Protection Act (in Dutch:, Algemene verordening gegevensbescherming, AVG) and the privacy regulation of the Amsterdam UMC, VU Medical Center Amsterdam.

Competing interests:

The authors declare that they have no competing interests.

Funding:

No external funding was received for this study.

Authors' contributions:

All authors participated in the design and the drafting of the manuscript. All authors have read an approved the final manuscript.

Acknowledgements:

Not applicable.

tor peer terien only



Figure 1 Inclusion procedure Figure 2 Control of alignment and randomization procedure

226x104mm (144 x 144 DPI)



Figure 3: follow-up scheme four versus six weeks plaster cast immobilization

IC: informed consent. X-ray: control X-ray according to standard guidelines, assessment using Lidström score. Function: functional assessment using PRWE, QuickDASH, SF-36, range of motion, VAS scale

Figure 3 Follow-up scheme four versus six weeks of plaster cast immobilization

196x132mm (144 x 144 DPI)

CONSORT

CONSORT 2010 checklist of information to include when reporting a randomised trial*
consort 2010 encernise of million to include when reporting a randomised in lar

Section/Topic	Item No	Checklist item	Reported
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design methods results and conclusions (for specific quidance see CONSORT for abstracts)	1
Intro duction			_
Background and	20	Scientific background and explanation of rationale	2
objectives	24	Specific objectives or hypotheses	3
objectives	20	Specific objectives of hypotheses	3
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	4
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	n.a.
Participants	4a	Eligibility criteria for participants	4
	4b	Settings and locations where the data were collected	4/5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	4-7
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	5
	6b	Any changes to trial outcomes after the trial commenced, with reasons	n.a.
Sample size	7a	How sample size was determined	7
	7b	When applicable, explanation of any interim analyses and stopping guidelines	n.a.
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	5
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	5
Allocation	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),	5
concealment mechanism		describing any steps taken to conceal the sequence until interventions were assigned	
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	5.6
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	6

CONSORT 2010 checklist

Page 1

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	n.a.
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	7.8
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	8
Results			
Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and	7
diagram is strongly		were analysed for the primary outcome	
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	7.8
Recruitment	14a	Dates defining the periods of recruitment and follow-up	6
	14b	Why the trial ended or was stopped	n.a.
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	study
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was	protocol
		by original assigned groups	na
Outcomes and	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its	study
estimation		precision (such as 95% confidence interval)	nrotocol
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	study
		pre-specified from exploratory	
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
Discussion			study
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	nrotocol
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	protocor
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
Other information			1
Registration	23	Registration number and name of trial registry	1
Protocol	24	Where the full trial protocol can be accessed, if available	12
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	12

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see <u>www.consort-statement.org</u>.

CONSORT 2010 checklist

 Page 2

BMJ Open

BMJ Open

Dislocated distal radial fractures in adult patients: Four weeks versus Six weeks of cast immobilisation following reduction, a multicenter randomized controlled trial, study protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-026540.R1
Article Type:	Protocol
Date Submitted by the Author:	27-Nov-2018
Complete List of Authors:	van Delft, Eva A.K.; Amsterdam UMC, Vrije Universiteit Amsterdam, Trauma surgery Bloemers, Frank; VU medisch centrum, Traumasurgery Sosef, Nico L; Spaarne Gasthuis, Trauma Surgery Bonjer, H.J. (Jaap); Amsterdam UMC, Vrije Universiteit Amsterdam, Surgery Schep, Niels W.L.; Maasstad Ziekenhuis, Trauma Surgery Vermeulen, Jefrey; Maasstad Ziekenhuis, Trauma Surgery
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Sports and exercise medicine
Keywords:	Adult orthopaedics < ORTHOPAEDIC & TRAUMA SURGERY, Hand & wrist < ORTHOPAEDIC & TRAUMA SURGERY, Orthopaedic & trauma surgery < SURGERY
	·

SCHOLARONE[™] Manuscripts

2			
3 4	1	TITLE PAGE	
5	2	Title: Dislocated di	stal radial fractures in adult patients: Four weeks versus Six weeks of
6 7	3	cast immobili	sation following reduction, a multicenter randomized controlled trial,
8	4	study protoco	bl.
9 10	5	Acronym: DR P	IP II study, study protocol (Distal radius plaster immobilisation period)
11	6	-	
12	7	Authors and affiliat	tions:
14	8	1. E.A.K. van De	Ift, MD, PhD candidate, surgical resident [corresponding author]
15 16	9	Affiliation:	Amsterdam UMC, Vrije Universiteit Amsterdam, Department of
17	10		Trauma Surgery, Amsterdam Movement Sciences
18 19	11	Address:	Boelelaan 1117, Amsterdam, The Netherlands
20	12	Email:	evavandelft@gmail.com
21 22	13	Phone:	0031-20444444
23	14	2. F.W. Bloemer	s, MD, PhD, MSc, trauma surgeon
24 25	15	Affiliation:	Amsterdam UMC, Vrije Universiteit Amsterdam,
25 26	16		Department of Trauma Surgery
27	17	Address:	Boelelaan 1117, Amsterdam, The Netherlands
28 29	18	Email:	fw.bloemers@vumc.nl
30	19	3. N.L. Sosef, M	D, trauma surgeon
31 32	20	Affiliation:	Spaarne Gasthuis Hospital, Department of Surgery
33	21	Address:	Boerhaavelaan 22, 2035 RC, Haarlem, The Netherlands
34 25	22	Email:	nsosef@spaarnegasthuis.nl
35 36	23	4. Prof. H.J. Bon	jer, MD, PhD, Professor of Surgery
37	24	Affiliation:	Amsterdam UMC, Vrije Universiteit Amsterdam,
38 39	25		Department of Surgery
40	26	Address:	Boelelaan 1117, Amsterdam, The Netherlands
41 42	27	Email:	j.bonjer@vumc.nl
43	28	5. N.W.L. Schep	, MD, PhD, MSc, trauma surgeon
44 45	29	Affiliation:	Maasstad Hospital, Department of Trauma and hand surgery
45 46	30	Address:	Maasstadweg 21, 3079 DZ, Rotterdam, The Netherlands
47	31	Email:	schepn@maasstadziekenhuis.nl
48 49	32	6. J. Vermeulen,	MD, PhD, MSc, trauma surgeon
50	33	Affiliation:	Maasstad Hospital, Department of Trauma surgery
51 52	34	Address:	Maasstadweg 21, 3079 DZ, Rotterdam, The Netherlands
53	35	Email:	vermeulenj@maasstadziekenhuis.nl
54 55	36	Trial registration:	Netherlands National Trial Register: NTR 6600, ABR: NL62861.029.17
56	37	Brotocol version	Medical Ethical Committee VUmc registration number: 2018.004
57	38 39	Fundina:	∠ no funding was obtained for this study
58 59	40	Responsibilities:	Project leader: F.W. Bloemers
60	41	Word count:	2260

Dislocated distal radial fractures in adult patients:

Four weeks versus Six weeks of cast immobilisation following reduction,

a multicenter randomized controlled trial, study protocol.

ABSTRACT

Introduction: Up to 30% of patients with a dislocated distal radius fracture treated with closed reduction and cast immobilisation suffer from long-term functional restrictions. It remains unclear, whether duration of cast immobilisation influences functional outcome. The aim of this study is to evaluate whether the functional outcome of dislocated distal radial fractures could be improved by shortening the period of immobilisation.

Methods and analysis: A single blinded multicenter randomized controlled trial is initiated. Four weeks of plaster cast immobilisation is compared to six week plaster cast immobilisation in adult patient with adequate reduced distal radial fractures. Primary outcome parameters are functional outcome measured with the Patient Rated Wrist Evaluation after 1 year of follow up. Secondary outcomes are: Disability of Arm, Shoulder and Hand Score after one year, SF-36 after one year, functional outcome earlier in follow up (6 weeks, 12 weeks and 6 months), range of motion, pain level and complications (number of re-interventions, secondary displacement, non-/malunion).

Ethics and dissemination: The medical ethical committee VUmc approved the study protocol (2018.004). The expectation of this study is that a shorter duration of plaster cast immobilisation is beneficial. This risk of specific complications is low and generally similar in both treatment options. Follow-up is standardized according to current trauma guidelines. Present literature indicates that both treatment options that are used within this study are accepted protocols for treatment of displaced distal radius fractures. This trial will provide level-1 evidence for the comparison of functional outcome between the two treatment options for dislocated distal radial fractures. Results of this study are expected to be published as a prospective, multicenter, randomized controlled trial article in 2021.

Keywords:

Trial registration:

Netherlands National Trial Register: NTR 6600, ABR: NL62861.029.17 Medical Ethical Committee VUmc registration number: 2018.004 Distal radial fractures, conservative treatment, immobilisation period

1	Strengths and limitations:
2	This study is designed as a single blinded study.
3	This multicenter study will be carried out in two hospitals in the Netherlands
4	 This studies uses validated outcomes (PRWE, QuickDASH, SF-36).
5	This studies uses both statistical as well as minimal clinical important difference.
6	This trial will provide level-1 evidence for the period of immobilisation in reduced distal
7	radial fractures.
8	
9	

INTRODUCTION

Distal radial fractures (DRF) are common fractures and account for up to 20% of all

- extremity fractures.[1] Most of these patients can be treated non-operatively in a plaster,
- with excellent functional results. [2,3] Nevertheless, up to 30% of patients with a dislocated
- DRF suffer from long-term functional restrictions following conservative treatment as
- neuropathy, arthrosis and stiffness .[4]

Unstable DRF are liable to displace within the first two weeks, only 7-8% displace after this

time and none after six weeks.[5-7] Therefore a period of up to six weeks of immobilisation

is advised, although, this is still a matter of debate in literature.[8,9]

Two prospective studies of patients with displaced and reduced DRF showed that a shorter immobilisation period was safe, without increased numbers of (re)dislocation of the fracture.[8,10] Besides, the outcome seemed to be better on the long term, in terms of wrist motion and grip strength. Unfortunately these studies were non-randomized and conducted in heterogeneous groups of patients suffering both non-dislocated and dislocated fractures. Obviously, the best treatment of reduced DRF will be short, safe and will lead to an early return of function. To assess whether reduction of the immobilisation period with two weeks will lead to better functional outcome, a multicenter randomized controlled trial will be conducted.

The patient reported functional outcome after one year will be assessed using validated instruments: The Patient Rated Wrist Evaluation (PRWE), the Quick Disability of Arm and Shoulder (DASH) and SF-36 forms.[11-13] Other outcome measures will be the functional outcome earlier in follow up, the amount of pain (VAS), number of secondary dislocations, number of re-interventions, range of motion, non-/malunion and complex regional pain syndrome (CRPS).

The aim of this trial is to compare the results of four weeks of cast immobilisation with six weeks of cast immobilisation in closed and adequate reduced DRF. Usually an immobilisation period of five or six weeks is preferred as non-operative treatment of closed and adequate reduced DRF. Despite the minimal evidence in literature this immobilisation period can be guestioned. A randomized clinical trial with sufficient power will be needed to provide scientific support for a preferred treatment strategy for reduced DRF.

1 ว						
2 3 4	1	METHODS AND ANALYSIS				
5	2	This study will be conducted as a prospective single blinded multicenter randomized clinical				
6 7	3	trial in two large teaching hospitals. In this study four weeks of plaster immobilisation will be				
8 9	4	compared with six weeks of plaster immobilisation.[Figure 1 and 2] Patients will be treated in				
10	5	a lower arm cast in neutral position.[14] Following immobilisation treatment will be the same				
11 12	6	for both groups, in which additional physiotherapy after removal of the cast is advised and				
13	7	exercises to train wrist function will be given. As extra structured advise programs may				
14 15	8	cause no extra benefit for the patient, this was not generally prescribed. [15] The Medical				
16 17	9	Ethics Committee VUmc, the Netherlands (2018.004) has approved the study protocol.				
18 19	10	Patient and Public involvement				
20 21	11	Evaluation of eligible patients will take place either at the emergency department or at the				
22	12	outpatient department. They will receive written information and a consent form from the				
23 24	13	attending physician, the clinical investigator or a research assistant. Patients will be eligible				
25 26	14	if they follow the in- and exclusion criteria:				
26 27	45					
28 29	15					
30	16	1. Age > 18 years;				
31 32	17	2. Primary displaced unilateral DRF;				
33	18	Independent for activities of daily living.				
34 35	19					
36 37	20	Exclusion criteria:				
38	21	1. Fracture of the contralateral wrist;				
39 40	22	2. Ipsilateral fractures proximal of the DRF;				
41 42	23	3. Pre-existent abnormalities or functional deficits of the fractured wrist that influences				
42 43	24	the patient reported function of the wrist;				
44 45	25	4. Open fractures;				
46	26	5. Language ability to understand the Dutch patient information and questionnaires.				
47 48	27					
49 50	28	Patients will only be able to participate if closed reduction of the distal radial fracture is				
50 51	20	adequate The indication for reduction will be set using the Lidström criteria for				
52 53	30	auequate. The indication for reduction will be set, using the Lidstrom Chiena for				
54	31	nisalignment. [10] Patients will only be able to participate in this study if reduction is				
55 56	37	performed succession. Succession reduction will be classified as. radial shortening <3mm, dorsal tilt <10° or intra articular step off <2mm, according the duidelines of the American				
57	32	Association of Orthonedic Surgeons [17]				
58 59 60	55					

After providing informed consent, eligible patients will be randomized after two weeks when the fracture has proven to be stable. An independent research assistant will perform concealed permuted block randomisation using a computer-generated randomisation schedule after stratification for fracture type, gender and age. Allocation will be at random in four blocks. To prevent bias, stratification by age (younger and older than 60 years) and gender will be performed.[table 1]

Table 1:Stratification by gender and age (younger and older than 60 years)

Stratification by gender and age				
Patien	t characteristics	Randomization		
List 1	Male <60 y.o.a.	ABAB AABB ABBA BABA BAAB		
List 2	Male >60 y.o.a.	BAAB BBAA ABAB AABB ABBA		
List 3	Female <60 y.o.a.	AABB ABBA BAAB BBAA BABA		
List 4	Female >60 y.o.a.	ABBA BABA ABAB AABB AABB		
A = fou	r weeks, B = six weeks			

Randomisation between another 2 or 4 weeks cast immobilisation will be performed to
complete a total of 4 and 6 weeks of cast immobilisation, respectively. Randomisation will
occur after informed consent.

The primary outcome measure of this study is PRWE after one year.[11] The secondary outcome measures are The QuickDASH score after one year[12]; The SF-36 Healthy Survey after one year[13]; Functional outcome after 8 weeks, 3 months and 6 months; Range of motion; Pain level after 8 weeks, 3 months, 6 months and 1 year; Lidström-score[16]; and fracture related complications as secondary dislocation after cast removal, number of reinterventions, delayed and non-unions and CRPS.

PRWE score is the most responsive instrument for evaluating the outcome in patients with DRF. The PRWE is a validated 15-item (scored 1-10), self-reported questionnaire designed to help describe the disability experienced by people with disorders of the wrist and also to monitor changes in symptoms and function over time. Scores will be transformed to a 0-100 score.[11] A higher score will indicate greater disability.

The DASH Outcome Measure is a validated 30-item, self-reported questionnaire designed
 to help describe the disability experienced by people with upper-limb disorders and also to
 monitor changes in symptoms and function over time.[17] The QuickDASH is a shortened
 version of the DASH Outcome Measure. Instead of 30 items, the QuickDASH uses 11 items

Page 7 of 18

1

BMJ Open

2		
3 4	1	(scored 1–5) to measure physical function and symptoms in people with any or multiple
5	2	musculoskeletal disorders of the upper limb. At least 10 of the 11 items must be completed
6 7 8	3	for a score to be calculated. The scores will be transformed to a 0–100 scale for easy
	4	comparison. A higher score will indicate greater disability.[12]
9 10	5	The SF-36 is a validated 36-item, self-reported questionnaire designed to describe the
11 12	6	quality of life. The score consists eight subgroups: vitality, mental health social role,
12 13	7	emotional role, physical role, general health, bodily pain, physical functioning. The
14 15	8	subgroups are transformed to a 0-100 scale. The lower the score will be, the more disability,
16	9	an higher score will indicate less disability.[13]
17 18	10	
19 20	11	After inclusion, all patients will be followed for one year in total. Clinical assessments will
21	12	occur at the time of admission (ED), one week (3-10-day window), two weeks (11-18-day
22 23	13	window), four weeks (24-32-day window) or six weeks (5-7-week window), three months
24 25	14	(11-15-week window), six months (5-7-month window), and 12 months (11-14-month
25 26 27	15	window) after inclusion.
28	16	At each follow up (FU) visit, the research coordinator or research assistant will ascertain
29 30	17	patient status (i.e., secondary interventions, adverse events/complications, deaths) and will
31 32	18	verify information within medical records. All adverse events will be addressed to the
33 34	19	principal investigator.
35	20	At each FU visit, the patients will be asked to indicate the actual pain level on a VAS.
30 37	21	Patients will also be asked if they have any complaints of their treatment and will be asked if
38 39	22	they are currently treated by a physical therapist. At each visit from eight weeks onwards,
40	23	the range of motion of the wrist will be measured using a goniometer, according to the
41 42	24	reference values for joint range of motion published by the American Academy of
43	25	Orthopaedic Surgeons [18] In addition, patients will be asked to complete the questionnaires
44 45 46	26	relating to disability (QuickDASH score, PRWE, SF-36).
47	27	Plain X-rays of the wrist will be made at the time of presentation in the hospital (ED), after
48 49	28	one and two weeks, 4 or 6 weeks and at the follow-up visit after eight weeks, three months,
50	29	six months and one year. The X-ray at one year will be taken in order to determine the
51 52	30	grade of degenerative joint changes. Time to define the presence of a delayed- or malunion
53 54	31	will be at three or six months.[figure 1-3]
55	27	
57	22	The primary outcome will be the Patient Pated Wrist Evaluation Score, of which the minimal
58 59	20	clinically important difference is 11.5 points. The standard deviation of the DDW/E is
60	54	Chinically important unreferice is 11.3 points. The standard deviation of the PRIVE IS

14.0.[19] Based on a difference of 11.5 points, the sample size of 27 patients per treatment
 group is calculated with a power (1-β) of 80 percent and a type I error (α) of 5 percent,
 allowing for 10 percent drop-out. In this study, we decided to include 45 patients per
 treatment group. To allow a 10 percent drop-out in this study, in total 100 patients will be
 included.

Data from the demographic data collection and the outcome parameters will be cleaned blindly from the treatment data. Data are presented as mean scores with 95% confidence intervals. The analysis of this study will be carried out according to the intention-to treat principle, i.e. the patients will remain in the group they will be randomly allocated to at baseline. Analysis of functional outcome will be assessed using repeated-measures analysis of variance (GLM 4) with the time as the within-group factor and the treatment as the between-group factor. Post-hoc analysis will be performed on the time of randomisation. Group comparisons at the different time points will be made only when the overall repeated-measures tests are statistically significant. All scores will be tested for normality using the Kolmogorov-Smirnov test. Parametric variables will be compared using the Student's t-test, while non-parametric and ordinal variables will be compared using the Mann-Whitney U statistic. Nominal variables will be compared across independent groups using the chi-squared test or Fisher's exact test. Homogeneity of variance will be assessed using Levene's test. Also, a multiple regression will be performed. SPSS statistical software (version 24.0) will be used for the analysis, in which two-tailed P value < 0.05 will be considered significant.

2		
3 4	1	ETHICS AND DISSEMINATION
5	2	Present literature indicates that four weeks of immobilisation as well as six weeks of
6 7	3	immobilisation are both accepted protocols for treatment of displaced DRF. In daily practise,
8	4	a six weeks immobilisation period is mostly used. To assess the clinical controversy on this
9 10	5	duration of treatment, this study is initiated.
11 12	6	The studies done for assessing the immobilisation periods of DRF have their limitations of
13	7	using non-validated outcome score lists, which makes it impossible to conclude with certainty
14 15	8	shorter immobilisation periods of DRF are preferred.
16	9	The expectation of this study is that a shorter duration of plaster cast immobilisation is
17 18	10	beneficial for the patients. This risk of specific complications is low and generally similar in
19 20	11	both treatment options.
20 21	12	
22 23	13	The Medical Ethical Committee VUmc has approved the study protocol (2018.004).
23 24	14	This trial will provide level-1 evidence for the comparison of functional outcome between the
25 26	15	two treatment options for dislocated DRF. Results of this study are expected to be published
27	16	as a prospective, multicenter, randomized controlled trial article in 2021.
28 29	17	
30		
31 32		
33 34		
35		
36 37		
38		
39 40		
41		
42 43		
44		
45 46		
47		
48 49		
50 51		
52		
53 54		
55		
56 57		
58		
59 60		

REFERENCES

- 1. Meena S, Sharma P, Sambharia AK, Dawar A, Fracture of Distal Radius: An overview. *J Family Medicine and Primary Care*, 2014; 3(4): 325-332.
- **2.** Cooney WP, Management of Colles' fractures. *J Hand Surg Br*, 1989;14(2): 137–139.
- **3.** McQueen M, Caspers J, Colles fracture: does the anatomical result affect the final function? *J Bone Joint Surg*, 1988; 70(4): 649–651.
- 4. Cooney WP, James M.D, Dobyns J.H, Linscheid R.L, Complications of Colles fractures. *J Bone Joint Surg Am*, 1980; 62(4): 613-619.
- **5. Solgaard S**, Early displacement of distal radius fracture. *Acta Orthopedica Scandinavia*, 1986; 57(3): 229–231.
 - 6. Abbaszadegan H, Sivers KV, Jonsson U, Late displacement of Colles' fractures. *Int Orthopedics*, 1988; 12(3): 197–199.
- **7.** Solgaard S, Function after distal radius fracture. *Acta Orthop Scand*, 1988; 59(1): 39–42.
 - 8. McAuliffe TB, Hilliar KM, Coates CJ, Grange WJ, Early mobilisation of Colles' fractures. *J Bone Joint Surg Br*, 1987; 69(5) :727-729.
 - **9.** Christensen OM, Christiansen TG, Krasheninnikhoff M, Hanssen FF, Length of immobilization after fractures of the distal radius. *Int Orthop*, 1995;19(1): 26-9.
 - **10. Vang Hansen F, Staunstrup H, Mikkelsen S**, A comparison of 3 and 5 weeks immobilisation for Older type 1 and 2 Colles' fractures. *J Hand Surg Br,* 1998; 23(3): 400-401.
 - **11. MacDermid JC, Turgeon T, Richards RS, Beadle M, Roth JH**, Patient rating of wrist pain and disability: a reliable and valid measurement tool. *J Orthop Trauma*, 1998; 12(8): 577–586.
 - **12. Gummesson C, Ward MM, Atroshi I,** The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH): validity and reliability based on responses within the full-length DASH. *BMC Musculoskelet Disord*, 2006; 7-44.
 - **13.** Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E, Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease, *J Clin Epidemiol*, 1998; 51(11): 1055-1068.
 - **14. Handol HHG, Madhok R,** Conservative interventions for treating distal radial fractures in adults. *Cochrane Database of Systematic Reviews,* 2003; (2):CD000314
 - **15.** Bruder AM, Shields N, Dodd KJ, Hau R, Taylor NF, A progressive exercise and structured advice program does not improve activity more than structured advice alone following a distal radial fracture: a multi-centre, randomised trial. *Journal of Physiotherapy*, 2016 ; 62:145-52
 - **16. Lidström A,** Fractures of the distal end of the radius: a clinical and statistical study of end results. *Acta Orthop Scand Suppl*, 195; 41:1–118.
 - **17. AAOS**, The treatment of distal radius fractures, guideline and evidence report, December 5, 2009.
- **18. Greene W, Heckman JD,** The Clinical Measurement of Joint Motion. Rosemont, IL: American Academy of Orthopaedic Surgeons, 1994.
- **19. Walenkamp MM, de Muinck Keizer RJ, Goslings JC, Vos LM, Rosenwasser MP, Schep MW,** The minimum clinically important Difference of the Patient-rated Wrist
 - For peer review only http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2 3 4 5	1 2	EvaulationSccore for Patients with distal radius fractures, <i>Clin Orthop Relat Res.</i> 2015 473(10):3235-41
6 7		
8 9		
10 11		
12 13 14		
14 15 16		
17 18		
19 20		
21 22 22		
23 24 25		
26 27		
28 29		
30 31 32		
33 34		
35 36		
37 38		
39 40 41		
42 43		
44 45		
46 47 48		
49 50		
51 52		
53 54		
55 56 57		
58 59		
60		

2 3 4	1	AUTHORS CONTRIBUTIONS				
5 6	2	<u>E.A.K. van De</u>	elft: Study development, writing study protocol,			
7	3		Clinical investigator in Amsterdam UMC, VU Medical Center			
8 9	4	F.W. Bloemer	s: Project leader, corrections of study protocol			
10	5	N.L. Sosef:	First clinical investigator in Spaarne Gasthuis			
11 12	6	Prof. H.J. Bon	jer: Head of department of Surgery Amsterdam UMC, VU Medical Center			
13 14	7		Approval of the study protocol			
15	8	N.W.L. Schep	: Study development			
16 17	9	J. Vermeulen:	_ Initial first clinical investigator in Spaarne Gasthuis,			
18	10		study development, Corrections of study protocol			
19 20	11		Ó			
21	12					
22 23 24	13	LIST OF A	BBREVIATIONS			
24 25 26 27 28 29 30 31 32 33 4 35 36 37 38 39 40 41 42 43 44 56 47 48 49 50 51 52 53 54 55 56 57 58 59 60	14	AAOS ABR AVG CRPS DASH ED IC METC NTR PRWE qDASH QuickDASH SPSS VAS VUmc X-ray	American Association of Orthopedic Surgeons ABR form, General Assessment and Registration form, is the application form that is required for submission to the accredited Ethics Committee (In Dutch, ABR = Algemene Beoordeling en Registratie) Algemene verordening gegevensbescherming (Dutch Data Protection Act) Complex regional pain syndrome Disability of Arm, Shoulder and Hand Emergency Department Informed Consent Medical research ethics committee (MREC) Nederlands Trial Register Patient Rated Wrist Evaluation Quick Disability of Arm, Shoulder and Hand Statistical Package for the Social Sciences Visual analogue scale Vrije Universiteit Medical Center Amsterdam Radiography			
	15	FIGURE L	EGENDS			
	16	Figure 1	Inclusion procedure			
	17	Figure 2	Control of alignment and randomization procedure			
	18	Figure 3	Follow-up scheme four versus six weeks of plaster cast immobilization			
	19					

Page 13 of 18

1

BMJ Open

2		
3 4	1	Ethics approval and consent to participate:
5	2	The study is submitted to the Medical Ethics Committee VU Medical Center Amsterdam and
6 7	3	Regional Ethical Committee and will be carried out in compliance with the Declaration of
8	4	Helsinki on Ethical principles for medical research involving human subjects. The Medical
9 10	5	Ethics Committee VU Medical Center Amsterdam acts as central ethics committee for this
11 12	6	trial (reference number: NL62861.029.17)
12	7	
14 15	8	Consent for publication:
16	9	All patients will provide informed consent before participation in the trial. The data will be
17 18	10	coded by patient number. Research data will be stored in a database (IBM SPSS Statistics
19	11	for Windows, Version 22.0. Armonk, NY: IBM Corp. Released 2013), and will be handled
20 21	12	confidentially and anonymously.
22	13	
23 24	14	Availability of data and materials:
25 26	15	The data will be coded by patient number. Research data will be stored in a database (IBM
20 27	16	SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. Released 2013), and will
28 29	17	be handled confidentially and anonymously. Research data that can be traced to individual
30	18	persons can only be viewed by authorized personnel. These persons are the members of the
31 32	19	research team, members of the health care inspection, and members of the Medical Ethics
33	20	Committee of the Amsterdam UMC, VU Medical Center Amsterdam. Review of the data may
34 35	21	be necessary to ensure the reliability and quality of the research. The handling of personal
36 37	22	data is in compliance with the Data Protection Act (in Dutch:, Algemene verordening
38	23	gegevens bescherming, AVG) and the privacy regulation of the Amsterdam UMC, VU
39 40	24	Medical Center Amsterdam.
41	25	
42 43	26	Competing interests:
44 45	27	The authors declare that they have no competing interests.
45 46	28	
47 48	29	Funding:
49	30	No external funding was received for this study.
50 51	31	
52	32	Authors' contributions:
53 54	33	All authors participated in the design and the drafting of the manuscript. All authors have
55 56	34	read an approved the final manuscript.
57	35	
58 59	36	Acknowledgements:
60	37	Not applicable.

Figure 1: Inclusion procedure



Figure 1 Inclusion procedure

227x59mm (300 x 300 DPI)





Figure 2 Control of alignment and randomization procedure

198x86mm (300 x 300 DPI)



Figure 3: follow-up scheme four versus six weeks plaster cast immobilization

IC: informed consent. X-ray: control X-ray according to standard guidelines, assessment using Lidström score. Function: functional assessment using PRWE, QuickDASH, SF-36, range of motion, VAS scale

Figure 3 Follow-up scheme four versus six weeks of plaster cast immobilization

145x97mm (300 x 300 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

RT 2010 checklist

of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
Introduction			
Background and	2a	Scientific background and explanation of rationale	3
objectives	2b	Specific objectives or hypotheses	3
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	4
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	n.a.
Participants	4a	Eligibility criteria for participants	4
	4b	Settings and locations where the data were collected	4/5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	4-7
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	5
	6b	Any changes to trial outcomes after the trial commenced, with reasons	n.a.
Sample size	7a	How sample size was determined	7
	7b	When applicable, explanation of any interim analyses and stopping guidelines	n.a.
Randomisation:			6
Sequence	8a	Method used to generate the random allocation sequence	5
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	5
Allocation	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),	5
concealment mechanism		describing any steps taken to conceal the sequence until interventions were assigned	
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	5.6
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	6

CONSORT 2010 checklist

Page 1

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	n.a.
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	7.8
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	8
Results			
Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and	7
diagram is strongly	iou	were analysed for the primary outcome	,
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	7.8
Becruitment	14a	Dates defining the periods of recruitment and follow-up	6
	14b	Why the trial ended or was stopped	<u> </u>
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	study
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was	protocol
	-	by original assigned groups	
Outcomes and	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its	ctudy
estimation		precision (such as 95% confidence interval)	study
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	protocor
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	n.d.
		pre-specified from exploratory	study
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	protocol
Discussion			n.a.
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	study
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	protocol
Interpretation	22	Interpretation consistent with results balancing benefits and barms and considering other relevant evidence	
	~~		
Other Information	22	Projection number and name of trial registry	1
Protocol	23	Where the full trial protocol can be accessed, if available	1
Fiblocol	24	Where the full that protocol can be accessed, it available	12
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see <u>www.consort-statement.org</u>.

CONSORT 2010 checklist

 Page 2

BMJ Open

BMJ Open

Dislocated distal radial fractures in adult patients: Four weeks versus Six weeks of cast immobilisation following reduction, a multicenter randomised controlled trial, study protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-026540.R2
Article Type:	Protocol
Date Submitted by the Author:	18-Dec-2018
Complete List of Authors:	van Delft, Eva A.K.; Amsterdam UMC, Vrije Universiteit Amsterdam, Trauma surgery Bloemers, Frank; VU medisch centrum, Traumasurgery Sosef, Nico L; Spaarne Gasthuis, Trauma Surgery Bonjer, H.J. (Jaap); Amsterdam UMC, Vrije Universiteit Amsterdam, Surgery Schep, Niels W.L.; Maasstad Ziekenhuis, Trauma Surgery Vermeulen, Jefrey; Maasstad Ziekenhuis, Trauma Surgery
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Sports and exercise medicine
Keywords:	Adult orthopaedics < ORTHOPAEDIC & TRAUMA SURGERY, Hand & wrist < ORTHOPAEDIC & TRAUMA SURGERY, Orthopaedic & trauma surgery < SURGERY
	·

SCHOLARONE[™] Manuscripts

2							
3 4	1	TITLE PAGE					
5	2	Fitle: Dislocated distal radial fractures in adult patients: Four weeks versus Six weeks of					
6 7	3	cast immobili	sation following reduction, a multicenter randomised controlled trial,				
8	4	study protoco	study protocol.				
9 10	5	Acronym: DR PIP II study, study protocol (Distal radial plaster immobilisation					
11	6	-					
12 13	7	Authors and affiliations:					
14	8	1. E.A.K. van De	lft, MD, PhD candidate, surgical resident [corresponding author]				
15 16	9	Affiliation:	Amsterdam UMC, Vrije Universiteit Amsterdam, Department of				
17	10		Trauma Surgery, Amsterdam Movement Sciences				
18 10	11	Address:	Boelelaan 1117, Amsterdam, The Netherlands				
20	12	Email:	evavandelft@gmail.com				
21	13	Phone:	0031-20444444				
22 23	14	2. F.W. Bloemer	s, MD, PhD, MSc, trauma surgeon				
24	15	Affiliation:	Amsterdam UMC, Vrije Universiteit Amsterdam,				
25 26	16		Department of Trauma Surgery				
27	17	Address:	Boelelaan 1117, Amsterdam, The Netherlands				
28	18	Email:	fw.bloemers@vumc.nl				
29 30	19	3. N.L. Sosef, M	D, trauma surgeon				
31	20	Affiliation:	Spaarne Gasthuis Hospital, Department of Surgery				
32 33	21	Address:	Boerhaavelaan 22, 2035 RC, Haarlem, The Netherlands				
34	22	Email:	nsosef@spaarnegasthuis.nl				
35 36	23	4. Prof. H.J. Bon	jer, MD, PhD, Professor of Surgery				
37	24	Affiliation:	Amsterdam UMC, Vrije Universiteit Amsterdam,				
38	25		Department of Surgery				
40	26	Address:	Boelelaan 1117, Amsterdam, The Netherlands				
41	27	Email:	j.bonjer@vumc.nl				
42 43	28	5. N.W.L. Schep	, MD, PhD, MSc, trauma surgeon				
44	29	Affiliation:	Maasstad Hospital, Department of Trauma and hand surgery				
45 46	30	Address:	Maasstadweg 21, 3079 DZ, Rotterdam, The Netherlands				
47	31	Email:	schepn@maasstadziekenhuis.nl				
48 40	32	6. J. Vermeulen,	MD, PhD, MSc, trauma surgeon				
50	33	Affiliation:	Maasstad Hospital, Department of Trauma surgery				
51 52	34	Address:	Maasstadweg 21, 3079 DZ, Rotterdam, The Netherlands				
52 53	35	Email:	vermeulenj@maasstadziekenhuis.nl				
54	36	Trial registration:	Netherlands National Trial Register: NTR 6600, ABR: NL62861.029.17				
55 56	37		Medical Ethical Committee VUmc registration number: 2018.004				
57	38 39	Protocol version: Funding:	ა no funding was obtained for this study				
58 59	40	Responsibilities:	Project leader: F.W. Bloemers				
60	41	Word count:	1952				

1 Dislocated distal radial fractures in adult patients:

2 Four weeks versus Six weeks of cast immobilisation following reduction,

a multicenter randomised controlled trial, study protocol.

5 ABSTRACT

Introduction: Up to 30% of patients with a dislocated distal radial fracture treated with
closed reduction and cast immobilisation suffer from long-term functional restrictions. It
remains unclear, whether duration of cast immobilisation influences functional outcome. The
aim of this study is to evaluate whether the functional outcome of dislocated distal radial
fractures could be improved by shortening the period of immobilisation.

Methods and analysis: A single blinded multicenter randomised controlled trial is initiated. Four weeks of plaster cast immobilisation is compared to six week plaster cast immobilisation in adult patient with adequate reduced distal radial fractures. Primary outcome parameters are functional outcome measured with the Patient Rated Wrist Evaluation after 1 year of follow up. Secondary outcomes are: Disability of Arm, Shoulder and Hand Score after one year, SF-36 after one year, functional outcome earlier in follow up (6 weeks, 12 weeks and 6 months), range of motion, pain level and complications: number of re-interventions, secondary dislocation, delayed and non-union.

Ethics and dissemination: The medical ethical committee VUmc approved the study protocol (2018.004, NL62861.029.17). The expectation of this study is that a shorter duration of plaster cast immobilisation is beneficial. This risk of specific complications is low and generally similar in both treatment options. Follow-up is standardized according to current trauma guidelines. Present literature indicates that both treatment options that are used within this study are accepted protocols for treatment of dislocated distal radial fractures. This trial will provide level-1 evidence for the comparison of functional outcome between the two treatment options for dislocated distal radial fractures. Results of this study are expected to be published as a prospective, multicenter, randomised controlled trial article in 2021.

31Trial registration:Netherlands National Trial Register: NTR 6600, ABR: NL62861.029.1732Medical Ethical Committee VUmc registration number: 2018.00433Keywords:Distal radial fractures, conservative treatment, immobilisation period

2		
3 ⊿	1	Strengths and limitations:
5	2	This study is designed as a single blinded study, it was not possible to perform this
6 7	3	study in a double blinded setting.
8	4	 This multicenter study will be carried out in two hospitals in the Netherlands.
9 10	5	 This stud uses validated outcomes (PRWE, QuickDASH, SF-36).
11 12	6	This study uses both statistical as well as minimal clinical important difference.
13	7	This trial will provide level-1 evidence for the period of immobilisation in reduced distal
14	8	radial fractures.
16 17	9	
$\begin{array}{c} 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ 60\\ \end{array}$	10	

INTRODUCTION

Distal radial fractures (DRF) are common fractures and account for up to 20% of all

extremity fractures.[1] Most of these patients can be treated non-operatively in a plaster with

excellent functional results. [2,3] Nevertheless, up to 30% of patients with a dislocated DRF

suffer from long-term functional restrictions following conservative treatment as neuropathy,

arthrosis and stiffness.[4]

Unstable DRF are liable to dislocate within the first two weeks, only 7-8% dislocate after this

time and none after six weeks.[5-7] Therefore a period of up to six weeks of immobilisation

is advised, although, this is still a matter of debate in literature.[8,9]

Two prospective studies of patients with dislocated and reduced DRF showed that a shorter immobilisation period was safe, without increased numbers of (re)dislocation of the fracture.[8,10] Besides, the outcome seemed to be better on the long term, in terms of wrist motion and grip strength. Unfortunately these studies were non-randomised and conducted in heterogeneous groups of patients suffering both non-dislocated and dislocated fractures. Obviously, the best treatment of reduced DRF will be short, safe and will lead to an early return of function. To assess whether reduction of the immobilisation period with two weeks will lead to better functional outcome, a multicenter randomised controlled trial will be conducted.

The patient reported functional outcome after one year will be assessed using validated instruments: The Patient Rated Wrist Evaluation (PRWE), the Quick Disability of Arm and Shoulder (DASH) and SF-36 forms.[11-13] Other outcome measures will be the functional outcome earlier in follow up, the amount of pain (VAS), number of secondary dislocations, number of re-interventions, range of motion, delayed and non-union and complex regional pain syndrome (CRPS).

The aim of this trial is to compare the results of four weeks of cast immobilisation with six weeks of cast immobilisation in closed and adequate reduced DRF. Usually an immobilisation period of five or six weeks is preferred as non-operative treatment of closed and adequate reduced DRF. Despite the minimal evidence in literature this immobilisation period can be guestioned. A randomised clinical trial with sufficient power will be needed to provide scientific support for a preferred treatment strategy for reduced DRF.

1	METHODS AND ANALYSIS				
2	This study will be conducted as a prospective single blinded multicenter randomised clinical				
3	trial in two large teaching hospitals. In this study four weeks of plaster immobilisation will be				
4	compared with six weeks of plaster immobilisation.[Figure 1 and 2] The methods of this stud				
5	protocol are comparable to a previous published article comparing three weeks of cast				
6	immobilisation to five weeks of cast immobilisation in adult patients with non displaced D				
7	[14,15] Patients will be treated in a lower arm cast in neutral position.[16] Following				
8	immobilisation, treatment will be the same for both groups, in which additional physiotherapy				
9	after removal of the cast is advised and exercises to train wrist function will be given. As				
10	extra structured advise programs may cause no extra benefit for the patient, this was not				
11	generally prescribed.[17] However, during follow-up visits, patients will be asked if they were				
12	treated by a physiotherapist. If this is the case, details on the number of sessions per week				
13	and the total number of weeks the patient received physiotherapy, will be collected.				
14	The Medical Ethics Committee VUmc, the Netherlands (2018.004) has approved the study				
15	protocol.				
16	Participants				
17	Evaluation of eligible patients will take place either at the emergency department or at the				
18	outpatient department. They will receive written information and a consent form from the				
19	attending physician, the clinical investigator or a research assistant. Patients eligible if they				
20	follow the in- and exclusion criteria:				
21	Inclusion criteria:				
22	1. Age > 18 years;				
23	2. Primary dislocated unilateral DRF;				
24	3. Independent for activities of daily living.				
25					
26	Exclusion criteria:				
27	1. Fracture of the contralateral wrist;				
28	2. Ipsilateral fractures proximal of the DRF;				
29	3. Pre-existent abnormalities or functional deficits of the fractured wrist that influences				
30	the patient reported function of the wrist;				
31	4 Open fractures				
27	5 Language ability to understand the Dutch nationt information and questionnaires				
22	o. Language ability to understand the Duton patient mornation and questionnalies.				
33					
34	Patients will only be able to participate if closed reduction of the distal radial fracture is				
35	adequate. The indication for reduction will be set, using the Lidström criteria for				
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35				

misalignment.[18] Patients will only be able to participate in this study if reduction is
performed successfully. Successful reduction will be classified as: radial shortening <3mm,
dorsal tilt <10° or intra-articular step-off <2mm, according the guidelines of the American

4 Association of Orthopedic Surgeons.[19]

5 After providing informed consent, eligible patients will be randomised after two weeks when

6 the fracture has proven to be stable. An independent research assistant will perform

7 concealed permuted block randomisation using a computer-generated randomisation

8 schedule after stratification for fracture type, gender and age. Allocation will be at random in

9 four blocks. To prevent bias, stratification by age (younger and older than 60 years) and

10 gender will be performed.[Table 1]

Table 1: Stratification by gender and age (younger and older than 60 years)

Patier	nt characteristics	Randomisation
List 1	Male <60 y.o.a.	ABAB AABB ABBA BABA BAAB
List 2	Male >60 y.o.a.	BAAB BBAA ABAB AABB ABBA
List 3	Female <60 y.o.a.	AABB ABBA BAAB BBAA BABA
List 4	Female >60 y.o.a.	ABBA BABA ABAB AABB AABB

 Randomisation between another 2 or 4 weeks cast immobilisation will be performed to
complete a total of 4 and 6 weeks of cast immobilisation, respectively. Randomisation will
occur after informed consent.

The primary outcome measure of this study is PRWE after one year.[11] The secondary outcome measures are The QuickDASH score after one year[12]; The SF-36 Healthy Survey after one year[13]; Functional outcome after 8 weeks, 3 months and 6 months; Range of motion; Pain level after 8 weeks, 3 months, 6 months and 1 year; Lidström-score[18]; and fracture related complications: secondary dislocation after cast removal, number of re-interventions, delayed and non-unions and CRPS.

PRWE score is the most responsive instrument for evaluating the outcome in patients with DRF. The PRWE is a validated 15-item (scored 1-10), self-reported guestionnaire designed to help describe the disability experienced by people with disorders of the wrist and also to monitor changes in symptoms and function over time. Scores will be transformed to a 0-100 score.[11] A higher score will indicate greater disability.

1 ว					
2 3	1	The DASH Outcome Measure is a validated 30-item, self-reported questionnaire designed			
4 5	2	to help describe the disability experienced by people with upper-limb disorders and also to			
6	3	monitor changes in symptoms and function over time.[19] The QuickDASH is a shortened			
/ 8	4	version of the DASH Outcome Measure. Instead of 30 items, the QuickDASH uses 11 items			
9 10	5	(scored 1–5) to measure physical function and symptoms in people with any or multiple			
11	6	musculoskeletal disorders of the upper limb. At least 10 of the 11 items must be completed			
12 13	7	for a score to be calculated. The scores will be transformed to a 0–100 scale for easy			
14 15	8	comparison. A higher score will indicate greater disability.[12]			
16	9	The SF-36 is a validated 36-item, self-reported questionnaire designed to describe the			
17 18	10	quality of life. The score consists eight subgroups: vitality, mental health social role,			
19	11	emotional role, physical role, general health, bodily pain, physical functioning. The			
20 21	12	subgroups are transformed to a 0-100 scale. The lower the score will be, the more disability,			
22 23	13	an higher score will indicate less disability.[13]			
23 24	14				
25 26	15	After inclusion, all patients will be followed for one year in total. Clinical assessments will			
27 28	16	occur at the time of admission (ED), one week (3-10-day window), two weeks (11-18-day			
28 29	17	window), four weeks (24-32-day window) or six weeks (5-7-week window), three months			
30 31	18	(11-15-week window), six months (5-7-month window), and 12 months (11-14-month			
32 33	19	window) after inclusion.			
34 35	20	At each follow up (FU) visit, the research coordinator or research assistant will ascertain			
36	21	patient status (i.e., secondary interventions, adverse events/complications, deaths) and will			
37 38	22	verify information within medical records. All adverse events will be addressed to the			
39 40	23	principal investigator.			
41 42	24	At each FU visit, the patients will be asked to indicate the actual pain level on a VAS.			
43	25	Patients will also be asked if they have any complaints of their treatment and will be asked if			
44 45	26	they are currently treated by a physical therapist. At each visit from eight weeks onwards,			
46 47	27	the range of motion of the wrist will be measured using a goniometer, according to the			
48	28	reference values for joint range of motion published by the American Academy of			
49 50	29	Orthopaedic Surgeons [20] In addition, patients will be asked to complete the questionnaires			
51 52	30	relating to disability (QuickDASH score, PRWE, SF-36).			
53 54	31	Plain X-rays of the wrist will be made at the time of presentation in the hospital (ED), after			
55	32	one and two weeks, 4 or 6 weeks and at the follow-up visit after eight weeks, three months,			
56 57	33	six months and one year. The X-ray at one year will be taken in order to determine the			
58	34	grade of degenerative joint changes. Time to define the presence of a delayed- or non-union			
59 60	35	will be at three or six months.[Figure 1-3]			

BMJ Open

2		
3 4	1	
5	2	The primary outcome will be the Patient Rated Wrist Evaluation Score, of which the minimal
6 7	3	clinically important difference is 11.5 points. The standard deviation of the PRWE is
8	4	14.0.[21] Based on a difference of 11.5 points, the sample size of 27 patients per treatment
9 10	5	group is calculated with a power (1- β) of 80 percent and a type I error (α) of 5 percent,
11	6	allowing for 10 percent drop-out. In this study, we decided to include 45 patients per
12 13	7	treatment group. To allow a 10 percent drop-out in this study, in total 100 patients will be
14 15	8	included.
16 17	9	Data from the demographic data collection and the outcome parameters will be cleaned
18	10	blindly from the treatment data. Data are presented as mean scores with 95% confidence
19 20	11	intervals. The analysis of this study will be carried out according to the intention-to treat
21 22	12	principle, i.e. the patients will remain in the group they will be randomly allocated to at
23	13	baseline. Analysis of functional outcome will be assessed using repeated-measures analysis
24 25	14	of variance (GLM 4) with the time as the within-group factor and the treatment as the
26	15	between-group factor. Post-hoc analysis will be performed on the time of randomisation.
27 28	16	Group comparisons at the different time points will be made only when the overall repeated-
29 30	17	measures tests are statistically significant. All scores will be tested for normality using the
31	18	Kolmogorov-Smirnov test. Parametric variables will be compared using the Student's t-test,
32 33	19	while non-parametric and ordinal variables will be compared using the Mann–Whitney U
34	20	statistic. Nominal variables will be compared across independent groups using the chi-
35 36	21	squared test or Fisher's exact test. Homogeneity of variance will be assessed using
37	22	Levene's test. Also, a multiple regression will be performed. SPSS statistical software
38 39	23	(version 24.0) will be used for the analysis, in which two-tailed P value < 0.05 will be
40 41	24	considered significant.
42	25	
43 44	26	Patient and public involvement
45	20	Patient and public involvement
46 47	27	is carried out, participante receive on appually undets on the program of the study by a
48 49	28	appaiely developed poweletter
50	29	specially developed newsletter.
51 52	30	
53		
54 55		
56		
57		
50 59		
60		
		c

BMJ Open

2		
3 4	1	ETHICS AND DISSEMINATION
5	2	Present literature indicates that four weeks of immobilisation as well as six weeks of
6 7	3	immobilisation are both accepted protocols for treatment of dislocated DRF. In daily practise,
8	4	a six weeks immobilisation period is mostly used. To assess the clinical controversy on this
9 10	5	duration of treatment, this study is initiated.
11	6	The studies done for assessing the immobilisation periods of DRF have their limitations of
12 13	7	using non-validated outcome score lists, which makes it impossible to conclude with certainty
14	8	shorter immobilisation periods of DRF are preferred
15 16	9	The expectation of this study is that a shorter duration of plaster cast immobilisation is
17	10	beneficial for the patients. This risk of specific complications is low and generally similar in
18	11	both treatment options
20	12	bour treatment options.
21	12	The Medical Ethical Committee VI line has approved the study protocol (2018 004)
23 24	14	The trial will provide level 1 evidence for the comparison of functional outcome between the
25	14	this that will provide level-1 evidence for the comparison of functional outcome between the
26 27	15	two treatment options for dislocated DRF. Results of this study are expected to be published
28	16	as a prospective, multicenter, randomised controlled trial article in 2021.
29 30	17	
31		
32 33		
34		
35 36		
37		
38 39		
40		
41 42		
43		
44 45		
46		
47 48		
49 50		
50 51		
52		
55 54		
55 56		
57		
58		
59 60		

REFERENCES

- 1. Meena S, Sharma P, Sambharia AK, Dawar A, Fracture of Distal Radius: An overview. *J Family Medicine and Primary Care*, 2014; 3(4): 325-332.
- **2.** Cooney WP, Management of Colles' fractures. *J Hand Surg Br*, 1989;14(2): 137–139.
- **3.** McQueen M, Caspers J, Colles fracture: does the anatomical result affect the final function? *J Bone Joint Surg*, 1988; 70(4): 649–651.
- Cooney WP, James M.D, Dobyns J.H, Linscheid R.L, Complications of Colles fractures. J Bone Joint Surg Am, 1980; 62(4): 613-619.
- **5. Solgaard S**, Early displacement of distal radius fracture. *Acta Orthopedica Scandinavia,* 1986; 57(3): 229–231.
 - 6. Abbaszadegan H, Sivers KV, Jonsson U, Late displacement of Colles' fractures. *Int Orthopedics*, 1988; 12(3): 197–199.
- **7.** Solgaard S, Function after distal radius fracture. *Acta Orthop Scand*, 1988; 59(1): 39–42.
 - 8. McAuliffe TB, Hilliar KM, Coates CJ, Grange WJ, Early mobilisation of Colles' fractures. *J Bone Joint Surg Br*, 1987; 69(5) :727-729.
 - **9.** Christensen OM, Christiansen TG, Krasheninnikhoff M, Hanssen FF, Length of immobilization after fractures of the distal radius. *Int Orthop*, 1995;19(1): 26-9.
 - **10. Vang Hansen F, Staunstrup H, Mikkelsen S**, A comparison of 3 and 5 weeks immobilisation for Older type 1 and 2 Colles' fractures. *J Hand Surg Br,* 1998; 23(3): 400-401.
 - **11. MacDermid JC, Turgeon T, Richards RS, Beadle M, Roth JH**, Patient rating of wrist pain and disability: a reliable and valid measurement tool. *J Orthop Trauma*, 1998; 12(8): 577–586.
 - **12. Gummesson C, Ward MM, Atroshi I,** The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH): validity and reliability based on responses within the full-length DASH. *BMC Musculoskelet Disord*, 2006; 7-44.
 - **13.** Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E, Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease, *J Clin Epidemiol*, 1998; 51(11): 1055-1068.
 - **14. Bentohami A, de Korte N, Sosef N, Goslings JC, Bijlsma T, Schep N,** Study protocol: non-displaced distal radial fractures in adult patients: three weeks vs. five weeks of cast immobilization: a randomized trial. *BMC Muscoloskeletal Disorders*, 2014, 15:24.
- **15. Bentohami A, van Delft EAK, Vermeulen J, Sosef NL, de Korte N, Bijlsma TS, Goslings JC, Schep NWL,** Non- or minimally displaced distal radial fractures in adult patients: three weeks versus five weeks of cast immobilization a randomized controlled trial. *J Wrist Surgery,* 2018.
 - **16. Handol HHG, Madhok R,** Conservative interventions for treating distal radial fractures in adults. *Cochrane Database of Systematic Reviews,* 2003; (2):CD000314
- **17. Bruder AM, Shields N, Dodd KJ, Hau R, Taylor NF,** A progressive exercise and
 structured advice program does not improve activity more than structured advice
 alone following a distal radial fracture: a multi-centre, randomised trial. *Journal of Physiotherapy, 2016 ; 62:145-52*

1		
2	1	10. Lidetuäre A. Freetures of the distel and of the radius, a clinical and statistical study.
4	1	of end results. Acta Orthon Scand Suppl. 195: 41:1–118
5	2	19 AAOS The treatment of distal radius fractures, guideline and evidence report
6	л Л	December 5, 2009
7 8	5	20 Greene W Heckman ID The Clinical Measurement of Joint Motion Rosemont II
9	6	American Academy of Orthonaedic Surgeons 1994
10	3 7	21. Walenkamp MM. de Muinck Keizer RJ. Goslings JC. Vos LM. Rosenwasser MP.
11 12	8	Schep MW. The minimum clinically important Difference of the Patient-rated Wrist
12	9	EvaulationSccore for Patients with distal radius fractures, Clin Orthop Relat Res.
14	10	2015 473(10):3235-41
15		
16 17		
18		
19		
20		
21 22		
23		
24		
25 26		
20 27		
28		
29		
30 31		
32		
33		
34 25		
36		
37		
38		
39 40		
41		
42		
43 44		
45		
46		
47 49		
40 49		
50		
51		
52 53		
54		
55		
56		
57 58		
59		
60		

2 3 4	1	AUTHORS	CONTRIBUTIONS
5 6	2	<u>E.A.K. van De</u>	elft: Study development, writing study protocol,
7	3		Clinical investigator in Amsterdam UMC, VU Medical Center
8 9	4	F.W. Bloemer	s: Project leader, corrections of study protocol
10	5	N.L. Sosef:	First clinical investigator in Spaarne Gasthuis
11 12	6	Prof. H.J. Bon	jer: Head of department of Surgery Amsterdam UMC, VU Medical Center
13 14	7		Approval of the study protocol
14	8	N.W.L. Schep	: Study development
16 17	9	J. Vermeulen:	_ Initial first clinical investigator in Spaarne Gasthuis,
18	10		study development, Corrections of study protocol
19 20	11		
21	12		
22 23 24	13	LIST OF A	BBREVIATIONS
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45	14	AAOS ABR AVG CRPS DASH ED IC METC NTR PRWE qDASH QuickDASH SPSS VAS VUmc X-ray	American Association of Orthopedic Surgeons ABR form, General Assessment and Registration form, is the application form that is required for submission to the accredited Ethics Committee (In Dutch, ABR = Algemene Beoordeling en Registratie) Algemene verordening gegevensbescherming (Dutch Data Protection Act) Complex regional pain syndrome Disability of Arm, Shoulder and Hand Emergency Department Informed Consent Medical research ethics committee (MREC) Nederlands Trial Register Patient Rated Wrist Evaluation Quick Disability of Arm, Shoulder and Hand Statistical Package for the Social Sciences Visual analog scale Vrije Universiteit Medical Center Amsterdam Radiography
47 48	15	FIGURE L	EGENDS
49	16	Figure 1	Inclusion procedure
50 51	17	Figure 2	Control of alignment and randomisation procedure
52 53 54 55 56 57 58 59 60	18	Figure 3	Follow-up scheme four versus six weeks of plaster cast immobilisation
	19		

Page 13 of 24

BMJ Open

1					
2 3	1	Ethics approval and consent to participate:			
4 5	2	The study is submitted to the Medical Ethics Committee VU Medical Center Amsterdam and			
6	3	Regional Ethical Committee and will be carried out in compliance with the Declaration of			
/ 8	4	Helsinki on Ethical principles for medical research involving human subjects. The Medical			
9 10	5	Ethics Committee VU Medical Center Amsterdam acts as central ethics committee for this			
11	6	trial (reference number: 2018.004/NL62861.029.17)			
12 13	7				
14	8	Consent for publication:			
15 16	9	All patients will provide informed consent before participation in the trial. The data will be			
17 19	10	coded by patient number. Research data will be stored in a database (IBM SPSS Statistics			
18 19	11	for Windows, Version 22.0. Armonk, NY: IBM Corp. Released 2013), and will be handled			
20 21	12	confidentially and anonymously.			
22	13				
23 24	14	Availability of data and materials:			
25 26	15	The data will be coded by patient number. Research data will be stored in a database (IBM			
20 27	16	SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. Released 2013), and will			
28 29 30 31 32 33 34 35	17	be handled confidentially and anonymously. Research data that can be traced to individual			
	18	persons can only be viewed by authorized personnel. These persons are the members of the			
	19	research team, members of the health care inspection, and members of the Medical Ethics			
	20	Committee of the Amsterdam UMC, VU Medical Center Amsterdam. Review of the data may			
	21	be necessary to ensure the reliability and quality of the research. The handling of personal			
36 37	22	data is in compliance with the Data Protection Act (in Dutch:, Algemene verordening			
38	23	gegevensbescherming, AVG) and the privacy regulation of the Amsterdam UMC, VU Medical			
39 40	24	Center Amsterdam.			
41 42	25				
43	26	Competing interests:			
44 45	27	The authors declare that they have no competing interests.			
46	28				
47 48	29	Funding:			
49 50	30	No external funding was received for this study.			
50 51	31				
52	32	Acknowledgements:			
54	33	Not applicable.			
55 56					
57 58					
59					
60					

Figure 1: Inclusion procedure



Inclusion procedure

227x59mm (300 x 300 DPI)





Control of alignment and randomisation procedure

198x86mm (300 x 300 DPI)



IC: informed consent. X-ray: control X-ray according to standard guidelines, assessment using Lidström score. Function: functional assessment using PRWE, QuickDASH, SF-36, range of motion, VAS scale

Follow-up scheme four versus six weeks of plaster cast immobilisation

145x97mm (300 x 300 DPI)

BMJ Open



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/it em	lte m No	Description	Page/ line	
Administra	Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Page 1, Line 1-5	
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Page 1, Line 36-37	
	2b	All items from the World Health Organization Trial Registration Data Set	Page 1, Line 36-40	
Protocol version	3	Date and version identifier	Page 1, Line 3	
Funding	4	Sources and types of financial, material, and other support	Page 1, Line 39	
Roles and responsibili	5a	Names, affiliations, and roles of protocol contributors	Page 1, Line 8-35 Page 12, Line 1-10	
ties	5b	Name and contact information for the trial sponsor	Page 1, line 14-18,40	
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	Page 12, line 1-10 Page 13, line 29-37	
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	n.a.	
Introducti on				
Backgroun d and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Page 4, Line 2-18	

Page 4, line 8-18

Page 4, ;ine 25-26

Page 5, line 2-3

Page 5, line 2-3

Page 5, line 19-30

Page 5/6, line 32-9

n.a.

n.a.

n.a.

Page 6, line 15-20

Page 6/7, line 15-11

Page 7, line 13-17

Description of trial design including type of trial (eg, parallel

6b Explanation for choice of comparators

2		ao	Explanation for choice of comparators
3 4	Objectives	7	Specific objectives or hypotheses
5 6 7 8 9 10	Trial design	8	Description of trial design including type of trial (eg, paral group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiorit exploratory)
11 12	Methods: F	Parti	cipants, interventions, and outcomes
13 14 15 16 17 18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
19 20 21 22 23 24	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
25 26 27 28	Interventio ns	11 a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
29 30 31 32 33 34		11 b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
35 36 37 38		11 c	Strategies to improve adherence to intervention protocols and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
40 41 42		11 d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
43 44 45 46 47 48 49 50 51	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, fina value, time to event), method of aggregation (eg, median proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
52 53 54 55 56 57 58 59 60	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)

Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	Page 8, line 2-8
Recruitme nt	15	Strategies for achieving adequate participant enrolment to reach target sample size	n.a.
Methods: A	ssig	gnment of interventions (for controlled trials)	
Allocation:			
Sequen ce generati on	16 a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Page 6, line 4-11
Allocatio n conceal ment mechani sm	16 b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Page 6, line 4-11
Implem entation	16 c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Page 6, line 5
Blinding (masking)	17 a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Page 8, line 9-10
	17 b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n.a.
Methods: D	Data	collection, management, and analysis	
Data collection methods	18 a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Page 8, line 9-24

1	
2	
3	
4	
5	
5	
0	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
10	
10	
19	
20	
21	
22	
23	
24	
25	
26	
20	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
50	
57	
38	
39	
40	
41	
42	
43	
44	
45	
46	
_ 1 0	
4/	
4ð	
49	
50	
51	
52	
53	
54	
55	
56	
50	
5/	
58	
59	

	18 b	Plans to promote participant retention and complete follow- up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	Page 8, line 9-24						
Data manageme nt	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	n.a.						
Statistical methods	20 a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	Page 8, line 9-24						
	20 b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Page 8, line 9-24						
	20 c	Definition of analysis population relating to protocol non- adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	Page 8, line 9-24						
Methods: M	loni	toring							
Data monitoring	21 a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	n.a. available in protocol						
	21 b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n.a available in protocol.						
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	n.a. available in protocol						
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n.a. available in protocol						
Ethics and	Ethics and dissemination								
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Page 9, line 13-17						

Protocol amendmen ts	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	n.a. available in protocol
Consent or assent	26 a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Page 5, line 17 Page 6, line 5-6
	26 b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n.a.
Confidenti ality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	available in protocol
Declaratio n of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Page 13, line 26-30
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	available in protocol
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n.a.
Disseminat ion policy	31 a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Page 8, line 27-29
	31 b	Authorship eligibility guidelines and any intended use of professional writers	Page 12, line 1-10
	31 c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n.a.
Appendic es			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	added
	Protocol amendmen ts Consent or assent Confidenti ality Declaratio n of interests Access to data Ancillary and post- trial care Disseminat ion policy Appendic es Informed consent materials	Protocol amendmen25Consent or assent262027Confidenti ality27Declaratio n of interests28Access to data29Ancillary and post- trial care30Disseminat ion policy31Disseminat ion policy31bi b c31b c31b c32Informed consent materials32	Protocol amendments25Plans for communicating important protocol modifications (eg. changes to eligibility criteria, outcomes, analyses) to relevant parties (eg. investigators, REC/IRBs, trial participants, trial registries, journals, regulators)Consent or assent26Who will obtain informed consent or assent from potential a trial participants or authorised surrogates, and how (see Item 32)26Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicableConfidenti ality27How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trialDeclaratio of interests28Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigatorsAncillary and post- trial care30Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions31Authorship eligibility guidelines and any intended use of professional writers31Plans, if any, for granting public access to the full protocol, c participant-level dataset, and statistical codeAppendic es32Model consent form and other related documentati

Biological	33	Plans for collection, laboratory evaluation, and storage of	n.a.
specimens		biological specimens for genetic or molecular analysis in	
		the current trial and for future use in ancillary studies, if	
		applicable	

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "<u>Attribution-NonCommercial-NoDerivs 3.0 Unported</u>" license.

to peet teriew only

BMJ Open

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
Introduction			
Background and	2a	Scientific background and explanation of rationale	3
objectives	2b	Specific objectives or hypotheses	3
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	4
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	n.a.
Participants	4a	Eligibility criteria for participants	4
	4b	Settings and locations where the data were collected	4/5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	4-7
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	5
	6b	Any changes to trial outcomes after the trial commenced, with reasons	n.a.
Sample size	7a	How sample size was determined	7
	7b	When applicable, explanation of any interim analyses and stopping guidelines	n.a.
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	5
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	5
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	5
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	5.6
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	6

CONSORT 2010 checklist

Page 1

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	n.a.
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	7.8
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	8
Results			
Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and	7
diagram is strongly		were analysed for the primary outcome	
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	7.8
Recruitment	14a	Dates defining the periods of recruitment and follow-up	6
	14b	Why the trial ended or was stopped	n.a.
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	study
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was	protocol
		by original assigned groups	na
Outcomes and	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its	study
estimation		precision (such as 95% confidence interval)	protocol
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	n a
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	study
		pre-specified from exploratory	nrotocol
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
Discussion			study
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	protocol
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	protocol
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
Other information			1
Registration	23	Registration number and name of trial registry	1
Protocol	24	Where the full trial protocol can be accessed, if available	12
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	12

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see <u>www.consort-statement.org</u>.

CONSORT 2010 checklist

 Page 2